The requirements of a specialist breast centre
Laura Biganzoli(Hospital of Prato), Philip Poortmans(Université Paris Sciences et Lettres), Romain Geiss(European Society for Paediatric Oncology), María Die Trill(International Psychoanalytical Association), Antonio Ponti(Piedmont Reference Center for Epidemiology and Cancer Prevention), Fátima Cardoso(Université Paris Cité), Jean Palussière(Institut Bergonié), Isabel T. Rubio(Clinica Universidad de Navarra), Tiina Saarto(Champalimaud Foundation), Sema Erdem(European CanCer Organisation), Maria Fjell(Oncology Nursing Society), Elżbieta Senkus(Gdańsk Medical University), Peter Naredi(European CanCer Organisation), Marko Skelin(European Society for Medical Oncology), Christiane Kühl(University of Bonn), Charlotte E. Coles(Philipps University of Marburg), Roberto C. Delgado Bolton(Universidad de La Rioja), Simon Oberst(Cancer Research UK), Lorenza Marotti, Anna Sapino(Candiolo Cancer Institute), Marc Beishon(European School of Oncology), Alberto Costa(European School of Oncology), Luigi Cataliotti(European School of Oncology), David Cameron(Edinburgh Cancer Research), Marco Rosselli Del Turco(European School of Oncology), Berta Sousa(European Society for Medical Oncology)
Cited by 195
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2019|2.2k